Shares of Chromocell Therapeutics Co. (NYSE:CHRO – Get Free Report) traded down 15.1% during trading on Friday . The company traded as low as $0.58 and last traded at $0.59. 153,515 shares traded hands during trading, an increase of 130% from the average session volume of 66,810 shares. The stock had previously closed at $0.69.
Chromocell Therapeutics Stock Down 15.1 %
The business’s 50 day moving average price is $0.65 and its two-hundred day moving average price is $0.92.
Chromocell Therapeutics Company Profile
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain.
See Also
- Five stocks we like better than Chromocell Therapeutics
- How to Use Stock Screeners to Find Stocks
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- Earnings Per Share Calculator: How to Calculate EPS
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Chromocell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromocell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
